Avoro Capital Advisors Reduces $8M in Ultragenyx Pharmaceutical Inc. ($RARE)

Avoro Capital Advisors has completely exited its position in Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE), according to its latest SEC filing. The fund sold all 330,000 shares it previously held, marking a 100% reduction in its stake. This move was reported as of November 14, 2025, and may not reflect Avoro's current holdings.

What Changed in Avoro Capital Advisors' Ultragenyx Position

Avoro Capital Advisors decided to cut its entire position in Ultragenyx by selling 330,000 shares. This brought its holdings in the company to zero, a significant change from its previous stake. The filing indicates a complete exit from the investment, reducing its share count to none.

Other Institutional Activity in Ultragenyx

Other major funds have been active in Ultragenyx as well. BlackRock, Inc. increased its holdings by 668,044 shares, ending with 7,299,598 shares valued at about $152.9 million. Vanguard Portfolio Management LLC added 5,385,992 shares, resulting in the same number of shares worth approximately $112.8 million. State Street Corp grew its stake by 718,395 shares to a total of 5,021,441 shares, valued at $105.2 million. AQR Capital Management LLC had a notable increase of 3,217,527 shares, bringing its holdings to 4,578,024 shares worth nearly $95.9 million.

Ultragenyx Pharmaceutical Inc. Stock Snapshot

Shares of Ultragenyx, trading under the ticker RARE on NasdaqGS, are priced around $24.35. The company has a market capitalization of approximately $2.4 billion and a forward P/E ratio of 25.23. Ultragenyx's stock has experienced a 52-week low of $18.29 and a high of $42.37. The stock's 50-day moving average is $24.06, while the 200-day moving average is $27.12. The company shows a current ratio of 2.02 and a quick ratio of 1.65, indicating a solid short-term financial position.

Recent Earnings

Ultragenyx reported revenues of $670 million, though it experienced a slight revenue decline of 2.2%. The company has a net margin of -90.9%, reflecting ongoing challenges in profitability. Its next earnings report is scheduled for August 4, 2026.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

Recent insider activity at Ultragenyx includes several notable transactions. On June 1, 2026, CFO Howard Horn sold 4,653 shares at an average price of $23.77 as part of a planned transaction. Earlier, on May 18, 2026, Shehnaaz Suliman sold 5,740 shares at $25.12, also under a planned sale. Conversely, on May 14, 2026, insiders including Shehnaaz Suliman, Amrit Ray, and Michael Narachi made unplanned purchases totaling over 40,000 shares.

Analysts Set New Price Targets

Analyst activity around Ultragenyx remains active. On May 21, 2026, Cantor Fitzgerald maintained a buy rating with a $96 target price. Guggenheim, on May 8, 2026, also maintained a buy rating, setting a target at $43. Wells Fargo and Barclays both reiterated buy ratings with targets of $47 and $43, respectively. On March 24, 2026, Goldman Sachs downgraded its rating to hold, with a target price of $25. The overall analyst consensus is a strong buy, with a mean target price of $52.05.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases. Headquartered in Novato, California, and led by CEO Dr. Emil D. Kakkis, the company develops and markets products like Crysvita for X-linked hypophosphatemia and Mepsevii for Mucopolysaccharidosis VII. Ultragenyx is involved in various partnerships and collaborations to advance its pipeline of innovative therapies.

Bottom Line

Avoro Capital Advisors' complete exit from Ultragenyx marks a significant shift in its investment strategy. Investors often track such filings to gauge institutional sentiment, although these positions are historical and might not reflect current holdings. Ultragenyx continues to be a focus for analysts, with a strong buy consensus and varied price targets indicating diverse expectations for its future performance.